key: cord-0886044-d2q0421p
authors: Peñalva, Germán; Benavente, Regina Sandra; Pérez-Moreno, María Antonia; Pérez-Pacheco, María Dolores; Pérez-Milena, Alejandro; Murcia, José; Cisneros, José Miguel
title: Effect of the coronavirus disease 2019 pandemic on antibiotic use in primary care
date: 2021-02-02
journal: Clin Microbiol Infect
DOI: 10.1016/j.cmi.2021.01.021
sha: a40cf500c59b28ebc2f6425df4651ee6a4feb631
doc_id: 886044
cord_uid: d2q0421p

nan

During the coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), disruption of antimicrobial stewardship interventions has become a matter of concern. Antimicrobial resistance and the many unintended negative clinical consequences resulting from antibiotic misuse and overuse will persist and may potentially be aggravated by the pandemic, making it necessary to measure its impact on antibiotic use in all health-care settings [1] .

Antibiotic consumption increased in hospitals during the pandemic [2, 3] ; however, no study has reported the effect on antibiotic use in the community. Our objective was to assess the impact of the COVID-19 pandemic on antibiotic prescribing in primary care in a region with an existing comprehensive antimicrobial stewardship programme for hospitals and primary-care centres, the PIRASOA programme [4] .

We conducted a before and after cross-sectional study comparing antibiotic use in the community in the first and second quarters (Q) of 2019 and the same quarters in 2020 (COVID-19 period). A lockdown was in force in the region from 14 March to 21 June 2020. Outpatient antibiotic use was assessed for the whole public primary health-care system of Andalusia, Spain, with 8069 physicians distributed in 1516 primary-care centres clustered in 26 health districts, serving a population of 8.4 million people. We calculated quarterly antibiotic use as defined daily doses per 1000 inhabitants per day (DID) for overall antibacterials for systemic use (WHO's ATC Classification System group J01), six antibiotic groups: J01A (tetracyclines), J01C (penicillins), J01D (other b-lactam antibacterials), J01E (sulphonamides and trimethoprim), J01F (macrolides, lincosamides and streptogramins) and J01M (quinolones), and five antibiotics considered as strategic for respiratory infections: amoxicillin-clavulanate, amoxicillin, cefuroxime, levofloxacin and azithromycin. Data were collected from the computerized pharmacy records of reimbursed and dispensed drugs, hosted by the Pharmacy Service of the Andalusian Health Service. Patient data were anonymized. The pooled DID for each variable was calculated as total defined daily dose prescribed to the total population. To assess the statistical significance of the differences between quarters, means or medians were compared for the 26 health-care districts data using paired Student's t-test or Wilcoxon log-rank test, as appropriate after checking for normality, using the IBM SPSS Statistics software, version 23.0 (IBM, Armonk, NY, USA).

We found that the overall use of antibiotics in the community decreased in the COVID-19 period compared with the pre-COVID-19 period. The mean reduction of total antibiotic consumption was e1.30 ± 1.18 DID between 2020Q1 and 2019Q1 (e7.6% pooled DID reduction; p <0.0001), whereas the mean reduction was e5.14 ± 1.31 DID between 2020Q2 and 2019Q2 (e36.8% pooled DID reduction; p <0.0001). The magnitude of this reduction was significantly greater between the second quarters than between the first quarters (mean difference 3.84 ± 1.40 DID; p <0.0001). Larger reductions were also observed between the second quarters in most antibiotic groups: penicillins (e9.6% difference between 2020Q1 and 2019Q1 versus e41.3% difference between 2020Q2 and 2019Q2), cephalosporins (e3.8% versus e24.6%), macrolides (e6.9% versus e48.6%) and quinolones (e9.3% versus e30.5%). Except for azithromycin, which remained stable, consumption of strategic antibiotics decreased between the first quarters, ranging from e6.7% (p 0.001) for cefuroxime to e10.8% (p <0.0001) for amoxicillin. Larger reductions were found between the second quarters for all the individual antibiotics under study, azithromycin included, ranging from e27.0% (p <0.0001) for amoxicillin-clavulanate to e55.6% (p <0.0001) for amoxicillin ( Table 1 ). The quarterly time-series evolution of antimicrobial consumption since 2014, the starting year of the PIRASOA programme, shows a decreasing trend that is consolidated during the first two quarters of 2020 (Fig. 1) .

Concomitantly, primary-care consultations dropped from 9 556 575 in 2019Q1 to 9 412 596 in 2020Q1 (e1.5%), and from 9 307 171 in 2019Q2 to 8 637 335 in 2020Q2 (e7.2%).

Our findings show that antibiotic use in primary care decreased during the COVID-19 pandemic period in our region, with the sharpest decline occurring in the second quarter of 2020, when the lockdown was more extensive. These data contrast with the increase reported in hospitals [2, 3] . Interestingly, azithromycin use remained stable between 2020Q1 and 2019Q1, dropping markedly in 2020Q2 compared with 2019Q2 (e49.4%). Such different behaviour from that of other antibiotics may have been due to changes in the indication for the use of azithromycin, which in the early stages of the pandemic was suggested to be effective in treating individuals with COVID-19 [5] . It would be relevant to know why this decline in total antibiotic consumption in the community happened. Confinement has probably contributed to this reduction because the use of masks and hygienic measures prevented other infections. The lockdown could have hampered outpatients' access to the healthcare system and to antibiotic prescriptions. Although telephone consultations were readily available, patients' worries about using health services might have reduced the demand for appointments related to infectious disease care, or increased the use of alternatives, such as hospital emergency units or the 112 telephone line. However, our results suggest that the decreased antibiotic prescriptions are not entirely explained by decreased primary-care consultations, but to a large part by a sustained change in prescribing patterns due to the long-term effect of the PIRASOA programme [6] .

Gaining access to that information may be useful to improve antimicrobial stewardship programmes in primary care. If these results are confirmed in other health systems, further studies are needed to determine whether this reduction in antibiotic use in the community during the pandemic has resulted in a favourable ecological impact.

The authors declare no conflict of interests. No funding has been received.

COVID-19: don't neglect antimicrobial stewardship principles!

COVID-19 and the potential long-term impact on antimicrobial resistance

Antibiotic prescription during the COVID-19 pandemic: a biphasic pattern

The PIRASOA programme: design, structure, organisation and indicators of a comprehensive regional institutional programme for the prevention and control of healthcare-associated infections and antimicrobial stewardship for hospitals and primary care settings in Andalusia, Spain

US hydroxychloroquine, chloroquine, and azithromycin outpatient prescription trends

Long-term impact of an educational antimicrobial stewardship programme in primary care on infections caused by extended-spectrum blactamase-producing Escherichia coli in the community: an interrupted timeseries analysis

We acknowledge the contribution to the critical revision of the manuscript of the members of the Scientific Committee of the